OUTCOMES OF SPIRONOLACTONE IN RA PATIENT VIA SF-36 (AN EXTENDED STUDY)
Author(s)
Prajapati S1, Syngle A2, Vohra K3, Iqbal MZ1, Ali AN1
1Aimst University, Sungai Petani, Malaysia, 2Healing touch clinic, Chandigarh, Malaysia, 3Punjabi University, Patiala, India
OBJECTIVES: To measure the Spironolactone response on SF-36 in naïve rheumatic arthritis patients for the duration of 24 weeks. METHODS: th and 24th week visit. SF-36 score were calculated as the end point minus the baseline score and was tested using Wilcoxon rank sum test by software SPSS-22. RESULTS: Short Form-36 score: Scores of eight domains of health instrument short form -36(SF-36) improve significantly (p<0.01 vs baseline) from 35±3.13 to 50 ± 3.74 after 12 weeks and up-to 55±3.26 after 24 weeks for Physical function, 44±2.35 to 58 ± 2.58 after 12 weeks and up-to 64±2.7 after 24 weeks for Role-Physical, 38±3.46 to 78 ± 3.07 after 12 weeks and up-to 84±2.35 after 24 weeks for Body-Pain, 34±1.68 to 43 ± 1.76 after 12 weeks and up-to 48±1.88 after 24 weeks for General Health, 36±3.66 to 70.8 ± 3.22 after 12 weeks and up-to 78±2.0 after 24 weeks for Social Function, 31±2.16 to 30 ± 2.29 after 12 weeks and up-to 37±2.25 after 24 weeks for Vitality, 22±1.91 to 30 ± 2.29 after 12 weeks and up-to 37±2.25 after 24 weeks for Role-emotional, 43±2.97 to 54 ± 2.88 after 12 weeks and up-to 62±2.76 after 24 weeks for mental health. CONCLUSIONS: The add-on therapy, spironolactone shown statistically significant improvement in score of all eight domains of SF-36 in 0-24 weeks. The response rate of spironolactone of therapy much higher in first 12 weeks while next 12 weeks shown less significant improvement rate RA patients.
Conference/Value in Health Info
2018-09, ISPOR Asia Pacific 2018, Tokyo, Japan
Value in Health, Vol. 21, S2 (September 2018)
Code
PRM49
Topic
Methodological & Statistical Research
Topic Subcategory
Confounding, Selection Bias Correction, Causal Inference
Disease
Musculoskeletal Disorders